Overview
- To observe the clinical analgesic effect, safety and adverse reactions of acetylaconitine.
- To study and analyze the main influencing factors of the acetylaconitine tablets.
Description
The outpatients/inpatients meeting the criteria are included into this study after signing the Informed Consent Form. The patients received 5 visits in total, which take place after the patients are included into the real-world study, on the 3rd day after enrollment and at the 1st, 4th, 8th and 12th weeks thereafter, in the form of outpatient follow-up, telephone follow-up and APP follow-up.
Eligibility
Inclusion Criteria:
- Patients with chronic pain > 1 month and VAS > 40 mm Patients who can take the acetylaconitine tablets orally
Exclusion Criteria:
- Patients who cannot communicate or receive follow-up Patients allergic to acetylaconitine Patients who have taken the acetylaconitine drugs orally